Veeva Systems (VEEV) Could Be 24% Undervalued On Eli Lilly Global Vault CRM Rollout

Eli Lilly’s decision to roll out Veeva Systems (VEEV) Vault CRM globally has put fresh attention on the stock, as investors weigh what a wider AI driven deployment could mean for future demand.

See our latest analysis for Veeva Systems.

The Eli Lilly rollout lands at a time when Veeva Systems’ share price has gained strong momentum, with a 30 day share price return of 25.86% and a 90 day return of 53.44%. However, the 1 year total shareholder return is still down 13.14%, pointing to enthusiasm building recently after a weaker prior year.

If you are looking beyond Veeva Systems for other AI focused opportunities in healthcare, this is a useful moment to scan the market using our screener for 44 healthcare AI stocks.

After Veeva Systems’ sharp move and with the stock now sitting close to analyst targets but still at a discount to some intrinsic estimates, the next step is to pin down where fair value really sits.

Most Popular Narrative: 24% Undervalued

The most followed narrative on Veeva Systems prices fair value at $320 per share, well above the last close of $243.75, which frames today’s move as only a partial catch up.

Veeva’s attraction is not simply that it sells software to pharmaceutical companies.

Its attraction is that it sits inside workflows where reliability, compliance, historical data, and institutional trust matter enormously. Those characteristics can produce customer relationships that are unusually long-lived and difficult to displace.

Read the complete narrative.

The fair value hinges on Veeva Systems keeping those deeply embedded workflows, steadily widening its product footprint, and converting that into stronger margins over time. The narrative leans heavily on sustained earnings growth and a premium profitability profile rather than any dramatic step change.

Result: Fair Value of $320 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors in Veeva Systems still need to watch for slower technology spending after large pharma mergers and the risk that Falcon’s AI monetisation falls short of expectations.

Find out about the key risks to this Veeva Systems narrative.

Another View: Veeva Systems Through The Earnings Lens

The SWS fair ratio based on Veeva Systems’ P/E tells a different story. The stock trades on 43.6x earnings, well above the global Healthcare Services average of 28.3x and above the 31.5x fair ratio, even though it sits below the 56.8x peer average. This raises the question of whether that difference offers a cushion or represents a valuation risk investors need to consider.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this Veeva Systems story sounds compelling but incomplete, take a moment to review the data yourself and decide how comfortable you are with the current pricing. To see what other investors are highlighting on the upside, check the 3 key rewards.

Looking for more investment ideas beyond Veeva Systems?

Do not stop with Veeva Systems. Use this momentum to widen your watchlist and hunt for opportunities that fit your own risk, return, and income preferences.

• Target potential mispricing by scanning companies that screen as 51 high quality undervalued stocks before the crowd starts paying closer attention.
• Strengthen portfolio resilience by focusing on businesses highlighted in our 88 resilient stocks with low risk scores and see which stocks the data suggests carry fewer red flags.
• Build a steadier income stream by reviewing companies featured in the 11 dividend fortresses and see which yields look sustainable on current fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com